Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA-Based Life Sciences VC Invests Up to $50M in Therapeutics Companies, With Strong Interests in Autoimmune Disease, CNS, Oncology, and More

4 Aug

A USA-based life sciences venture capital and company formation firm with billions of dollars under management is currently investing out of their latest fund that closed last year. The firm will make equity investments of approximately $30–50 million over the lifetime of the company and can either lead investments or co-invest. The firm considers investment opportunities worldwide.

The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from preclinical (2–3 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.

The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: CVC Fund Invests Up to $10M, Actively Seeking Novel Drug Delivery Systems in Oncology, Cardiovascular, Chronic Disease, and Pulmonary Indications

4 Aug

A corporate venture arm of a leading electronic solutions provider focuses on medical and pharmaceutical sectors, among other areas. The firm is actively looking to build and expand their pipeline and will focus on strategic investments in which the firm could bring significant value and those that supplement the firm’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but will look at Seed stage within the life science space. The firm usually invests around $1-5M initially and reserves capital for follow-on investment. The firm has a global footprint, with manufacturing plants throughout USA and Asia. The firm is open to global opportunities including those in rapidly growing markets such as China and India.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also looks at technology relating to other chronic illness, consumer health & wellness, and point of care diagnostic systems. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA. Recently, the firm has invested in a novel inhaled insulin delivery device.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border Investment Firm Actively Looks For First in Class, Early-Stage Therapeutics Companies Across All Indications Globally

4 Aug

A cross-border venture capital firm with headquarters in Asia and additional offices in USA, is backed by some large pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry.   Remiges Ventures only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Invests Opportunistically in All Life Science Sectors in CNS, Nephrology, Dermatology and More in North America & Europe

4 Aug

A VC based in Western Europe invests opportunistically within the indications of nephrology, dermatology, urology, CNS/brain and orphan indications. The firm invests in companies from seed-Series A, up to 2M EUR. The firm is currently focused on European companies, but may consider companies based in North America as well.

Within the indications of interest, the firm is willing to consider companies in all sectors, therapeutics, medical devices, diagnostics and digital health. For therapeutic companies, the firm prefers the companies have some preclinical data, and be about a year from initiating clinical trials. For diagnostics companies, The firm prefers the companies be no more than 1 year from commercialization.

The firm can both lead or co-invest, and they may or may not take a board seat, depending on how they can help the company. The firm believes in promoting gender equality, and a large number of their investments are in female-led startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare and Technology-Focused VC Invests Broadly Across Healthcare in US, Asia, and Europe, With Strongest Interests in Therapeutics

28 Jul

A healthcare and technology focused venture capital fund based in USA an Europe only makes equity investments into private companies and has no specific preference in the investment stage. The firm primarily invests in companies that are based in the United States, China, Japan, India, and Europe. The firm is actively seeking new investment opportunities.

The firm is currently looking for new investment opportunities in Biopharmaceutical, Therapeutics and Diagnostics, Medtech, R&D services, and Healthcare IT. Generally the firm invests 65% in Therapeutics, 15%-20% into Medtech/Diagnostics and 15%-20% into HIT/Sevices.

The firm highly prefers to invest in companies with a strong and experienced management team. However, the firm is flexible within specific cases. The firm works with their portfolio companies together to create value for patients and providers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Investment Group Seeks Opportunities That Strategically Align With Parent Company’s Interests in Medtech, Open to Companies Across the Globe

28 Jul

A corporate investment group that invests strategically on behalf of their parent company uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to the parent company’s business groups: Cardiovascular, Restorative Therapies (including spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, and neurovascular devices), Diabetes, and Minimally Invasive Therapies (including general surgery, gastrointestinal care, pulmonology, and respiratory care and monitoring technologies). The firm is interested in diversifying the parent company’s product and services offerings within all of these groups and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Fund Seeks All Therapeutic Areas as Well as Medtech and Digital Health, Allocating Up to $20M in Series A Financings and Beyond

28 Jul

A firm actively funds, supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings and the size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the firm can invest directly as a Series A investment along with participation in related Series B investments. The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly and supportive of first-time CEOs, the firm works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: